Msi-specific frameshift peptides (fsps) for the prevention and treatment of cancer

A specific, frame-shifting technology, applied in the direction of cancer antigen components, antibody medical components, medical preparations containing active ingredients, etc., can solve the problem of insufficient immune response, weak immunogenicity, and inability to induce strong effector T-cells Activation and other issues

Active Publication Date: 2018-06-22
UNIVERSITY OF HEIDELBERG
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most tumors express antigens that are recognized to varying degrees by the host immune system, but in many cases the immune response is inadequate
Poor immunogenicity of tumor antigens or inappropriate expression or loss of expression of tumor cell co-stimulatory molecules can lead to inability to elicit robust activation of effector T-cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Msi-specific frameshift peptides (fsps) for the prevention and treatment of cancer
  • Msi-specific frameshift peptides (fsps) for the prevention and treatment of cancer
  • Msi-specific frameshift peptides (fsps) for the prevention and treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Detection of FSP-specific T cells in peripheral blood from MSI colon cancer patients and healthy HNPCC mutation carriers

[0060] (A) method (ELISpot assay)

[0061] Quantification of FSP-specific peripheral blood Tc by measuring the number of secreted gamma-interferon (IFN-γ) Tc specific for newly designed FSP derived from 3 cMS-containing candidate genes using ELISpot assay Frequency of cells (pTc). ELISpot assays were performed using 96-well nitrocellulose plates (Multiscreen; Millipore, Bedford, MA) coated with mouse anti-human γ-interferon monoclonal antibody (mAb) ( Mabtech, Naka, Sweden) overnight and blocked with serum-containing medium. Sixfold pTc (0 days, lxl0 5 / well) and autologous CD-40-activated B cells as antigen-presenting cells (4xl0 4 / well, single addition of TiBc or pBC) was plated in 200 μl of IMDM medium containing 10% human AB serum. Peptides were added to a final concentration of 10 μg / ml. As a positive control, peripheral blood T cells ...

Embodiment 2

[0076] Detection of FSP-specific humoral immune responses in peripheral blood from healthy HNPCC mutation carriers and colon cancer patients with MSI

[0077] (A) Method (ELISA)

[0078] For enzyme-linked immunosorbent assay (ELISA), peptides at a concentration of 40 μg / ml in PBS were coated onto 96-well polystyrene microplates 'Maxisorp' (Nunc, Roskilde, Denmark) at 4 ℃ overnight. After coating, plates were rinsed 4 times with PBS (0.05% Tween) and blocked with 0.5% casein in PBS for 1 hour. Peptide binding to microplates and optimal saturating peptide concentrations were assessed using the alkaline phosphatase-peptide competition assay. To monitor the individual background response of each serum, use the INK4a A control peptide for the protein (p16_76-105), against which no antibody reactivity was found in a large cohort of individuals (Reuschenbach et al., 2008). Individual sera were diluted 1:100 with blocking buffer (0.5% casein in PBS) and assayed in duplicate for ...

Embodiment 3

[0082] Detection of FSP-specific cytotoxic T cell responses

[0083] The expression of CD107a on the surface of T effector cells when stimulated with clinical FSP antigen was determined. The CD107a assay was used to demonstrate the secretion of perforin / granzyme B-containing cytotoxic granules from effector cells. CD107a molecules are expressed on the surface of cytotoxic granules and are detectable on the cell surface if the granules are released in the context of a cytotoxic T cell response.

[0084] To determine the potential of FSP peptides to induce cytotoxic cellular immune responses, blood was drawn from healthy donors and T cells were stimulated with FSP using dendritic cells as antigen presenting cells. Stimulation was repeated weekly with a time span of four weeks. Four weeks later, T cells were harvested, co-cultured with target cells, and the FSP CD107a assay was used to analyze the peptide-specific induction of cytotoxic T cell responses.

[0085] In the presen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A vaccine for the prevention and treatment of cancers characterized by microsatellite instability (MSI) is described, said vaccine comprising an MSI-specific frameshift peptide (FSP) or a nucleic acid encoding said FSP, the frameshift The peptides generate humoral and cellular responses against tumor cells. The vaccine of the present invention is particularly useful for the prevention / treatment of colorectal cancer, endometrial cancer, gastric cancer or small intestine cancer.

Description

technical field [0001] The present invention provides a vaccine for the prevention and treatment of cancers characterized by microsatellite instability (MSI). The vaccine comprises an MSI-specific frameshift peptide (FSP) or nucleic acid encoding said FSP, which produces a humoral or cellular response against tumor cells. Background technique [0002] Human tumors develop through two major pathways of genomic instability: chromosomal instability and microsatellite instability (MSI) due to defects in the DNA mismatch repair system. MSI is present in 15% of colorectal cancers and various extraintestinal malignancies displaying a defective DNA mismatch repair system, including endometrial, gastric, small bowel, and other organ tumors. MSI cancers can occur sporadically or in hereditary neoplastic syndromes, hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch syndrome. [0003] MSI colorectal tumors are characterized by high immunogenicity, which arises during the deve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/00
CPCA61K39/0011A61P35/00
Inventor 马提亚·克洛尔米里亚姆·雷乌舍恩巴赫马格纳斯·万克内贝尔-多伊贝里茨
Owner UNIVERSITY OF HEIDELBERG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap